Scans, taken every other month, first showed the
tumors shrinking dramatically and then indicated
no evidence of cancer.
Pritchard was fortunate. The study results from the
trial arm he participated in showed that just about
20 percent of patients with otherwise untreatable
bladder tumors responded to the immunotherapy
treatment. About 25 percent of patients whose tumors
had high levels of PD-L1 expression responded. In May
2016, the FDA approved Tecentriq to treat advanced or
metastatic urothelial carcinoma that hasn't responded
to platinum-based chemotherapy, making it the first
PD- 1 or PD-L1 inhibitor approved to treat the disease.
In April 2017, the FDA extended the drug’s approval
as a first-line treatment for people with locally
advanced or metastatic urothelial carcinoma who
aren’t eligible for treatment with cisplatin.
Your doctor may tell you that your chemotherapy treatment will most likely lead to
hair loss. In addition to scalp hair loss, you may also lose your eyebrows. While scalp
hair loss can be disguised, the loss of eyebrows can be di;cult to conceal and is often
perceived by patients as an unwelcome, visible sign of their illness.
RMV Trademarks, LLC, has developed a unique, patented product called EES-Essential
Eyebrow Solution®. EES is a clinically-tested, topical formulation that is used
cosmetically to address eyebrow thinning or loss, while conditioning and revitalizing
the brows. EES is safe and non-irritating, paraben-free, hypoallergenic, and pH
A recent EES clinical trial published in PRIME International Journal of Aesthetic &
Anti-Ageing Medicine demonstrated that 91% of the 117 enrolled cancer patients
retained 50-100% of their eyebrow hair while undergoing chemotherapy
treatment, despite experiencing full body hair loss elsewhere. The article
“Preserving Eyebrow Hair during Chemotherapy Treatment” was written in
collaboration with Josephine Ford Cancer Institute/Henry Ford Health System,
located in Detroit, Michigan.
Introducing EES – Essential Eyebrow Solution®
. . . A Solution for a Problem
TO LEARN MORE ABOUT EES, please visit www.essentialeyebrowsolution.com, or call 1-888-208-5081.
Chemotherapy regimen consisted of: Perjeta, Taxotere,
Carboplatin & Herceptin (every 3 weeks x 6 cycles),
followed by Herceptin every 3 weeks for 1 year.
The ability to maintain my natural eyebrows
during my treatment made a signi;cant
psychological di;erence when dealing with
my other losses. With a wig, eyeliner and the
preservation of my own eyebrows, others
frequently commented on their amazement
that I had not lost my hair... when indeed I
had. The loss of eyelashes and the hair on
one’s head are far easier to conceal than the
loss of one’s eyebrows. Thank you for the
opportunity to use this product during my
” — Lynn
Patient retained her eyebrows despite
full body hair loss elsewhere
Bladder cancer survivor Karl Pritchard enrolled in a clinical trial
for a PD-L1 inhibitor prior to its approval by the U.S. Food and
Drug Administration for treating bladder cancer. He currently
has no evidence of disease.